keyword
MENU ▼
Read by QxMD icon Read
search

esophagogastric adenocarcinoma

keyword
https://www.readbyqxmd.com/read/28637800/pharmacokinetics-biodistribution-and-radiation-dosimetry-for-89-zr-trastuzumab-in-patients-with-esophagogastric-cancer
#1
Joseph A O'Donoghue, Jason S Lewis, Neeta Pandit-Taskar, Stephen E Fleming, Heiko Schoder, Steven M Larson, Volkan Beylergil, Shutian Ruan, Serge Lyashchenko, Pat B Zanzonico, Wolfgang Andreas Weber, Jorge A Carrasquillo, Yelena Y Janjigian
Trastuzumab with chemotherapy improves clinical outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive esophagogastric adenocarcinoma (EGA). Despite the therapeutic benefit, responses are rarely complete and the majority of patients develop progression. This is the first report evaluating (89)Zr-trastuzumab in HER2-positive EGA in which we evaluate the safety, pharmacokinetics, biodistribution, and dosimetry. Methods: Trastuzumab was conjugated with deferoxamine and radiolabeled with (89)Zr...
June 21, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28628843/preoperative-chemotherapy-versus-chemoradiotherapy-in%C3%A2-locally-advanced-adenocarcinomas-of-the-oesophagogastric-junction-poet-long-term-results-of%C3%A2-a-controlled-randomised-trial
#2
Michael Stahl, Martin K Walz, Jorge Riera-Knorrenschild, Martin Stuschke, Andreas Sandermann, Michael Bitzer, Hansjochen Wilke, Wilfried Budach
BACKGROUND: Results of the PreOperative therapy in Esophagogastric adenocarcinoma Trial (POET) showed some benefits when including radiotherapy into the preoperative treatment. This article is reporting long-term results of this phase III study. PATIENTS AND METHODS: Patients with locally advanced adenocarcinomas of the oesophagogastric junction (Siewert types I-III) were eligible. Randomisation was done to chemotherapy (group A) or induction chemotherapy and chemoradiotherapy (CRT; group B) followed by surgery...
June 16, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28561677/immunotherapy-for-esophageal-and-gastric-cancer
#3
Ronan J Kelly
PD-L1 upregulation occurs in approximately 40% of gastroesophageal cancers. However, unlike other solid tumors, there is minimal PD-L1 expressed on the cancer cells; rather, expression occurs predominantly on infiltrating myeloid cells. Preliminary clinical data involving single-agent PD-1/PD-L1 inhibitors in metastatic gastroesophageal cancer have reported response rates of 22%-27% for patients with PD-L1(+) tumors and 10%-17% for unselected patients. The phase III ONO-4538-12 (ATTRACTION 2) trial has demonstrated an improved overall survival for nivolumab compared with placebo for patients with heavily pretreated gastric cancer...
2017: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/28556024/cancer-of-the-esophagus-and-esophagogastric-junction-major-changes-in-the-american-joint-committee-on-cancer-eighth-edition-cancer-staging-manual
#4
Thomas W Rice, Donna M Gress, Deepa T Patil, Wayne L Hofstetter, David P Kelsen, Eugene H Blackstone
Answer questions and earn CME/CNE New to the eighth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual for epithelial cancers of the esophagus and esophagogastric junction are separate, temporally related cancer classifications: 1) before treatment decision (clinical); 2) after esophagectomy alone (pathologic); and 3) after preresection therapy followed by esophagectomy (postneoadjuvant pathologic). The addition of clinical and postneoadjuvant pathologic stage groupings was driven by a lack of correspondence of survival, and thus prognosis, between both clinical and postneoadjuvant pathologic cancer categories (facts about the cancer) and pathologic categories...
May 26, 2017: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/28551654/overexpression-of-egfr-as-an-independent-prognostic-factor-in-adenocarcinoma-of-the-esophagogastric-junction
#5
Kenichi Aratani, Shuhei Komatsu, Daisuke Ichikawa, Takuma Ohashi, Mahito Miyamae, Wataru Okajima, Taisuke Imamura, Jun Kiuchi, Keiji Nishibeppu, Toshiyuki Kosuga, Hirotaka Konishi, Atsushi Shiozaki, Hitoshi Fujiwara, Kazuma Okamoto, Hitoshi Tsuda, Eigo Otsuji
BACKGROUND: Adenocarcinoma of the esophagogastric junction (AEG) has increased in Western and Eastern countries, and its prognosis remains poor. We tested whether epidermal growth factor receptor (EGFR), that is overexpressed in various tumors, acts as a cancer-promoting gene through overexpression in AEG. MATERIALS AND METHODS: We analyzed 104 primary AEG tumors which were curatively resected in our hospital between 2000 and 2010. RESULTS: Overexpression of EGFR protein was detected in 47% primary AEG tumor samples, and significantly associated with venous and lymphatic invasion, tumor depth and lymph node metastasis...
June 2017: Anticancer Research
https://www.readbyqxmd.com/read/28529581/expression-of-serum-and-glucocorticoid-regulated-kinase-1-and-its-association-with-clinicopathological-factors-and-the-survival-of-patients-with-adenocarcinoma-of-the-esophagogastric-junction
#6
Shegan Gao, Dan Wang, Guoqiang Kong, Shuoguo Li, Wei Wang, Huizhi Wang, Fuyou Zhou
While the aberrant expression and the controversial results of serum- and glucocorticoid-regulated kinase (SGK1) have been reported in a number of malignancies, the expression of SGK1 and its possible association with the progression of adenocarcinoma in the esophagogastric junction (AEG) remain to be elucidated. To the best of our knowledge, the expression and localization of SGK1 was examined for the first time in the present study in cancerous and adjacent tissue from 60 patients with AEG, and compared with 20 healthy mucosa control tissue samples...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28503799/lymph-node-dissection-for-siewert-ii-esophagogastric-junction-adenocarcinoma-a-retrospective-study-of-136-cases
#7
Xiaofeng Duan, Xiaobin Shang, Peng Tang, Hongjing Jiang, Zhentao Yu
BACKGROUND: To compare the lymph node dissection with the right transthoracic Ivor-Lewis (IL) procedure to that with the left transthoracic (LT) approach for Siewert type II adenocarcinoma of the esophagogastric (AEG) junction. METHODS: In this study, 136 patients with Siewert type II AEG who met the inclusion criteria underwent surgical resection were divided into the IL (47 cases) and LT (89 cases) groups. The number and frequency of the dissected lymph nodes in each station were compared between the two groups...
May 14, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28501091/update-on-gastroesophageal-adenocarcinoma-targeted-therapies
#8
REVIEW
Steven B Maron, Daniel V T Catenacci
Gastroesophageal cancer (GEC) remains a major cause of cancer-related mortality worldwide. Although the incidence of distal gastric adenocarcinoma (GC) is declining in the United States, proximal esophagogastric junction adenocarcinoma (EGJ) incidence is rising. GC and EGJ, together, are treated uniformly in the metastatic setting as GEC. Overall survival in the metastatic setting remains poor, with few molecular targeted approaches having been successfully incorporated into routine care to date-only first-line anti-HER2 therapy for ERBB2 amplification and second-line anti-VEGFR2 therapy...
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28501090/antiangiogenic-therapy-in-gastroesophageal-cancer
#9
REVIEW
Zhaohui Jin, Harry H Yoon
Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-naïve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus...
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28487609/optimal-treatment-for-siewert-type-ii-and-iii-adenocarcinoma-of-the-esophagogastric-junction-a-retrospective-cohort-study-with-long-term-follow-up
#10
Kei Hosoda, Keishi Yamashita, Hiromitsu Moriya, Hiroaki Mieno, Masahiko Watanabe
AIM: To determine the optimal treatment strategy for Siewert type II and III adenocarcinoma of the esophagogastric junction. METHODS: We retrospectively reviewed the medical records of 83 patients with Siewert type II and III adenocarcinoma of the esophagogastric junction and calculated both an index of estimated benefit from lymph node dissection for each lymph node (LN) station and a lymph node ratio (LNR: ratio of number of positive lymph nodes to the total number of dissected lymph nodes)...
April 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28487496/programmed-death-1-polymorphisms-is-associated-with-risk-of-esophagogastric-junction-adenocarcinoma-in-the-chinese-han-population-a-case-control-study-involving-2-740-subjects
#11
Weifeng Tang, Shuchen Chen, Yu Chen, Jihong Lin, Jiangbo Lin, Yafeng Wang, Chao Liu, Mingqiang Kang
Single nucleotide polymorphisms (SNPs) in Programmed cell death 1 (PD-1) gene may contribute to the development of cancer. In this study, we selected PD-1 rs10204525 T>C, rs2227982 A>G, rs36084323 T>C and rs7421861 A>G polymorphisms and designed a hospital-based case-control study to determine the potential relationship between these functional SNPs in PD-1 gene and esophagogastric junction adenocarcinoma (EGJA) risk. A total of 1,063 EGJA patients and 1,677 controls were enrolled from Eastern Chinese Han population...
June 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28475744/clinical-characteristics-and-associated-factors-of-japanese-patients-with-adenocarcinoma-of-the-esophagogastric-junction-a-multicenter-clinicoepidemiological-study
#12
K Matsueda, N Manabe, N Toshikuni, Y Sato, T Watanabe, H Yamamoto, K Haruma
Gastroesophageal reflux disease-related diseases, such as Barrett's esophagus and adenocarcinoma of the esophagogastric junction (AEGJ), are believed to occur less frequently in Asia than in Western countries. However, the number of reported cases is increasing, yet little is known regarding the epidemiology of AEGJ in Japan. The primary study aim is to investigate the clinicoepidemiological characteristics of AEGJ. The secondary aim is to identify factors associated with it. In the 6.5 years between January 2008 and June 2014, we reviewed 88,199 esophagogastroduodenoscopy (EGD) reports and associated medical records (Study 1)...
June 1, 2017: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/28447060/different-regimens-of-perioperative-chemotherapy-for-esophagogastric-and-gastric-adenocarcinoma-does-a-triplet-therapy-with-taxane-generate-a-survival-benefit
#13
EDITORIAL
Nicole Samm, Alexander Novotny, Helmut Friess, Daniel Reim
No abstract text is available yet for this article.
2017: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28429196/expression-of-programmed-cell-death-protein-1-by-tumor-infiltrating-lymphocytes-and-tumor-cells-is-associated-with-advanced-tumor-stage-in-patients-with-esophageal-adenocarcinoma
#14
Dagmar Kollmann, Desislava Ignatova, Julia Jedamzik, Yun-Tsan Chang, Gerd Jomrich, Matthias Paireder, Ivan Kristo, Dmitry Kazakov, Michal Michal, Antonio Cozzio, Wolfram Hoetzenecker, Tobias Schatton, Reza Asari, Matthias Preusser, Emmanuella Guenova, Sebastian F Schoppmann
BACKGROUND: Despite recent advances in the therapy for adenocarcinoma of the esophagogastric junction (AEG), overall prognosis remains poor. Programmed cell death protein 1 (PD1) is a co-inhibitory receptor primarily expressed by T-cells. Tumor cells can escape anticancer immune responses by triggering the PD1 pathway. Moreover, PD1 receptor engagement on cancer cells may trigger tumor-intrinsic growth signals. This study aimed to evaluate the potential clinical relevance of PD1 expression by tumor-infiltrating lymphocytes (TILs) and cancer cells in the AEG...
April 20, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28425657/different-time-trend-and-management-of-esophagogastric-junction-adenocarcinoma-in-three-asian-countries
#15
Waku Hatta, Daniel Tong, Yeong Yeh Lee, Shin Ichihara, Noriya Uedo, Takuji Gotoda
Esophagogastric junction (EGJ) adenocarcinoma has been on the increase in Western countries. However, in Asian countries, data on the incidence of EGJ adenocarcinoma are evidently lacking. In the present review, we focus on the current clinical situation of EGJ adenocarcinoma in three Asian countries: Japan, Hong Kong, and Malaysia. The incidence of EGJ adenocarcinoma has been reported to be gradually increasing in Malaysia and Japan, whereas it has stabilized in Hong Kong. However, the number of cases in these countries is comparatively low compared with Western countries...
April 2017: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/28425656/considering-the-esophagogastric-junction-as-a-zone
#16
Shin Ichihara, Noriya Uedo, Takuji Gotoda
Siewert's classification of adenocarcinoma of the esophagogastric junction (EGJ) classifies tumors anatomically for determining the appropriate surgical technique. According to this classification, a type II tumor, true carcinoma of the cardia, is defined as a cancer within 1 cm proximal to 2 cm distal of the EGJ. Histological analysis indicates that the cardiac gland is present with a high degree of frequency between 1-2 cm to the gastric side and 1-2 cm to the esophageal side of the EGJ, which means that this zone can be considered as neither the stomach nor the esophagus but rather as a third zone known as the 'EGJ zone'...
April 2017: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/28425653/endoscopic-gastric-mucosal-atrophy-distinguishes-the-characteristics-of-superficial-esophagogastric-junction-adenocarcinoma
#17
Noriya Uedo, Toshiyuki Yoshio, Shigetaka Yoshinaga, Manabu Takeuchi, Waku Hatta, Tomonori Yano, Tokuma Tanuma, Osamu Goto, Akiko Takahashi, Daniel Tong, Yeong Yeh Lee, Yoshiko Nakayama, Shin Ichihara, Takuji Gotoda
BACKGROUND AND AIM: Western studies have suggested two distinct etiologies of esophagogastric junction (EGJ) cancer: Helicobacter pylori-associated atrophic gastritis and non-atrophic gastric mucosa resembling esophageal adenocarcinoma. The present study investigated whether endoscopic gastric mucosal atrophy can distinguish between these two types of EGJ adenocarcinoma. METHODS: Data were collected from patients with Siewert type II, T1 EGJ adenocarcinoma who underwent endoscopic or surgical resection at eight Japanese institutions in 2010-2015...
April 2017: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/28412759/preoperative-monocyte-lymphocyte-and-neutrophil-lymphocyte-but-not-platelet-lymphocyte-ratios-are-predictive-of-clinical-outcomes-in-resected-patients-with-non-metastatic-siewert-type-ii-iii-adenocarcinoma-of-esophagogastric-junction-a-prospective-cohort-study
#18
Jia-Wei Zhang, Lei Huang, A-Man Xu
AIMS: To propectively reveal the clinicopathological and prognostic significances of monocyte-lymphocyte ratio (MLR), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in resected patients with non-metastatic Siewert type II/III adenocarcinoma of esophagogastric junction (AEG). METHODS: A total of 611 patients diagnosed with Siewert type II/III AEG and undergoing surgery between 2006 and 2011 were prospectively followed-up until April 2016. Associations between preoperative peripheral MLR, NLR, and PLR and clinicopathological parameters were quantified using the multivariate Logistic regression model with adjustment...
February 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28383418/new-evidence-guiding-extent-of-lymphadenectomy-for-esophagogastric-junction-tumor-application-of-ber-ep4-joint-with-cd44v6-staining-on-the-detection-of-lower-mediastinal-lymph-node-micrometastasis-and-survival-analysis
#19
Bin Zheng, Chen-Hui Ni, Hao Chen, Wei-Dong Wu, Zhao-Hui Guo, Yong Zhu, Wei Zheng, Chun Chen
For Siewert type II adenocarcinoma of the esophagogastric junction (AEJ), the optimal surgical approach and extent of lymph nodes dissection remain controversial. Immunohistochemistry (IHC) has been reported to be available for identifying lymph node micrometastasis (LNMM) in patients with AEJ. This was a prospective case series of patients who underwent R0 resection and lower mediastinal lymphadenectomy from January 2010 to June 2015 in Fujian Medical University Union Hospital for Siewert type II AEJ. The outcomes were analyzed retrospectively...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28337865/helicobacter-pylori-and-barrett%C3%A2-s-esophagus-a-protective-factor-or-a-real-cause
#20
REVIEW
G Tomasello, F Giordano, M Mazzola, R Jurjus, A Jurjus, P Damiani, S Nobile, F Carini, A Leone
Notwithstanding the definite aetiopathogenetic path of certain diseases, the relationship between Helicobacter pylori (H. pylori) and Barrett’s esophagus (BE), a condition that increases the risk for dysplasia and consequently adenocarcinoma of the distal esophagus and esophagogastric junction, remains uncertain. This paper reviews the current scientific literature with emphasis on the protective correlation between H. pylori infection and BE and demonstrates that a causal relationship has not been disproved with certainty...
January 2017: Journal of Biological Regulators and Homeostatic Agents
keyword
keyword
105953
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"